mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment. As ...

The most recent trading session ended with Moderna (MRNA) standing at $57.73, reflecting a -0.96% shift from the previouse trading day's closing. This change lagged the S&P 500's daily gain of 0.77%.

In addition to Pfizer and Moderna's new formulas, Novavax's protein-based shot is an option for COVID vaccination this season ...

The rise in mRNA pharmaceuticals’ licensing agreement values suggests that this field will remain a major area for innovation ...

An mRNA vaccine that targets several aspects of C. difficile’s ability to cause severe disease prevented major symptoms and death in mice.

Messenger RNA (mRNA) serves as a blueprint for proteins. When mRNA is no longer needed, it must be degraded. Director Elena ...

MRNA Vaccines: "The University of Sheffield's versatile RNAbox builds on the 'vaccine revolution' experienced during the ...

Researchers have been working on mRNA flu vaccines since before the Covid-19 pandemic, but we may get one for bird flu first.

Engineers have discovered a simple and inexpensive means of directing lipid nanoparticles (LNPs), the revolutionary molecules that delivered the COVID-19 vaccines, to target specific tissues, ...

Researchers from University of Science and Technology of China (USTC) published data for a novel multivalent mRNA mpox vaccine candidate, MPXV-1103.

This growth has continued into 2024, with the rising value of licensing agreements reflecting growing confidence in this technology beyond application in vaccines. Global sales for innovator mRNA ...